MicroRNA 1273f: A Drug Target / Disease Biomarker (G100616156)

Target Name: MicroRNA 1273f

NCBI ID: G100616156

MicroRNA 1273f

Other Name(s): MIR1273F

MicroRNA 1273f: A Drug Target / Disease Biomarker

MicroRNA (miRNA) 1273f is a non-coding RNA molecule that plays a critical role in regulating gene expression in various organisms, including humans. It is a member of the 1273 microRNA family, which is known for its ability to interact with target mRNAs and regulate their stability.

Recent studies have identified miRNA 1273f as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its unique mechanism of action and its potential as a therapeutic target make it an attractive target for researchers and clinicians.

The mechanism of action of miRNA 1273f is based on its ability to interact with specific target mRNAs and regulate their stability. This interaction between miRNA and its target RNA can lead to the either activation or repression of gene expression. The levels of miRNA 1273f in the cell can be regulated by various factors, including the levels of its precursor RNA, the stability of its translation products, and interactions with other microRNAs and proteins.

Studies have shown that miRNA 1273f can interact with several target mRNAs, including but not limited to:

1. p53: MiRNA 1273f has been shown to interact with the tumor suppressor gene p53, which plays a critical role in regulating cell growth and apoptosis. p53 mutations have been linked to the development of various diseases, including cancer. Therefore, targeting p53 with miRNA 1273f may be a promising strategy for cancer therapy.
2. NF-kappa-B: NF-kappa-B is a protein that plays a role in cell signaling and inflammation. MiRNA 1273f has been shown to interact with the NF-kappa-B protein, which can lead to the regulation of various cellular processes, including cell growth, differentiation, and inflammation. Therefore, targeting NF-kappa-B with miRNA 1273f may be a potential strategy for therapeutic interventions aimed at reducing inflammation and promoting tissue repair.
3. TGF-β: TGF-β is a protein that plays a role in cell signaling and development. MiRNA 1273f has been shown to interact with the TGF-β protein, which can lead to the regulation of various cellular processes, including cell growth, differentiation, and inflammation. Therefore, targeting TGF-β with miRNA 1273f may be a potential strategy for therapeutic interventions aimed at promoting tissue growth and development, and potentially reducing the risk of certain diseases.

In addition to its potential as a drug target, miRNA 1273f has also been identified as a potential biomarker for various diseases. Its expression levels can be regulated by various factors, including but not limited to:

1. Disease stage: MiRNA 1273f expression levels can be affected by the stage of disease, with higher levels of expression observed in certain stages of cancer. Therefore, monitoring miRNA 1273f expression levels in disease-specific samples may be a promising strategy for diagnostic purposes and evaluating the effectiveness of therapeutic interventions.
2. Disease severity: MiRNA 1273f expression levels can also be influenced by the severity of disease, with higher levels of expression observed in more severe diseases. Therefore, monitoring miRNA 1273f expression levels in disease-specific samples may be a useful tool for evaluating the effectiveness of therapeutic interventions and determining the potential for different treatments.
3. Patient response: MiRNA 1273f expression levels can also be influenced by a patient's response to therapeutic interventions. For example, higher levels of miRNA 1273f expression in response to

Protein Name: MicroRNA 1273f

The "MicroRNA 1273f Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MicroRNA 1273f comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets